RxDoctor Payments Data

Elizabeth Settle

Acute Care · Nashville, TNNPI 1972086775

Payments from drug & device makers

$929in general payments, 2019–2025

Across 33 payments — averaging $28.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Solventum Corporation$276
  • AbbVie$249
  • Argenx US, Inc.$63
  • Takeda Pharmaceuticals U.S.A., Inc.$61
  • Pfizer$61
  • SK Life Science, Inc.$50
  • plus $168 from 7 others

What the payments were for

  • Food & beverage$89396%
  • Education$364%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$929 in reported general payments places this provider in the 70th percentile of 738 acute care providers in Tennessee.

See all acute care providers in Tennessee

Medicare billing

Part B allowed, 2024
$2,498,106
Medicare patients
162
Services billed
3,633

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm61$42,105
Nurtec OdtRimegepant Sulfate27$40,886
UbrelvyUbrogepant21$30,703
EliquisApixaban31$27,157
TopamaxTopiramate12$21,590
Aimovig AutoinjectorErenumab-Aooe22$20,816
LamictalLamotrigine12$18,777
QuliptaAtogepant14$14,966
Emgality SyringeGalcanezumab-Gnlm13$9,238
BrilintaTicagrelor11$5,996
Levetiracetam190$5,532
Lacosamide83$5,503
Oxcarbazepine31$5,413
Depakote SprinkleDivalproex Sodium11$4,298
Aspirin-Dipyridamole ErAspirin/Dipyridamole28$3,317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Eliquis$61$68,04358 claims
AbbVieUbrelvy, Qulipta$249$45,66935 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 738 acute care providers in Tennessee.

Other acute care in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →